IRP
REGN icon

Investment Research Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

Investment Research Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$301K Buy
483
+199
+70% +$135K 0.1% 213
2026
Q1 		$219K Sell
284
-11
-4% -$8.42K 0.09% 218
2025
Q4 		$228K Buy
+295
New +$200K 0.1% 208

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Investment Research Partners's REGN Position: Q2 2026 in Review

Investment Research Partners increased its Regeneron Pharmaceuticals (REGN) stake by 70% in Q2 2026, buying an estimated $135K and bringing the position to 483 shares worth $301K. The position accounts for 0.1% of the portfolio, ranked #213.

Investment Research Partners first reported a position in REGN in Q4 2025 and has held it in 3 quarters since. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Investment Research Partners held 483 shares of Regeneron Pharmaceuticals worth $301K as of Q2 2026.
  • Investment Research Partners bought 199 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $135K.
  • Regeneron Pharmaceuticals made up 0.1% of Investment Research Partners's portfolio in Q2 2026, its #213 holding.
  • Investment Research Partners first reported a position in Regeneron Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Investment Research Partners's 13F filing for Q2 2026, filed 4 Aug 2026.